Joyce A. O'Shaughnessy, MD
Co-Director, Breast Cancer Research
Baylor Charles A Sammons Cancer Center
Texas Oncology/The US Oncology Network
Kathy S. Albain, MD, FACP
Professor of Medicine
Division of Hematology/Oncology
Loyola University Chicago Stritch School of Medicine
Director, Breast Clinical Research Program
Director, Thoracic Oncology Program
Cardinal Bernardin Cancer Center
David Euhus, MD
Director, Mary L. Brown Breast Cancer Genetics and Risk Assessment Program
UT Southwestern Center for Breast Care
Silvia C. Formenti, MD
Professor of Medicine
Sandra and Edward H. Meyer Professor of Radiation Oncology
Chair, Department of Radiation Oncology
NYU Radiation Oncology Associates
NYU Langone Medical Center
New York, NY
Frankie Ann Holmes, MD
Breast Cancer Research Committee
Texas Oncology/Houston Memorial City
Stephen E. Jones, MD
US Oncology Research
Terry Mamounas, MD, MPH, FACS
Professor of Surgery
Northeastern Ohio Medical University
Medical Director, Aultman Cancer Center
Beth Overmoyer, MD
Director, Inflammatory Breast Cancer Program
Assistant Professor of Medicine
Harvard Medical School
Andrew D. Seidman, MD
Attending Physician, Breast Cancer Medicine Service
Memorial Sloan-Kettering Cancer Center
Professor of Medicine
Joan and Sanford I. Weill Medical College of Cornell University
New York, NY
Ian E. Smith, MD
Professor of Cancer Medicine
The Royal Marsden Hospital
Institute of Cancer Research
London, United Kingdom
Debu Tripathy, MD
Professor of Medicine
Co-Leader, Women’s Cancer Program
Priscilla and Art Chair in Women’s Cancer
University of Southern California
Norris Comprehensive Cancer Center
Los Angeles, CA
This activity features highlights from the recent "10th Annual Controversies in Breast Cancer: Adjuvant and Neoadjuvant Therapy," a day-long symposium featuring a diverse panel of internationally recognized breast cancer experts who presented and led in-depth discussions on the increasing number of breast cancer subtypes that challenge oncologists. A significant emphasis on real cases and new data supporting local and systemic adjuvant and neoadjuvant treatment options helped to provide practical context for the evolving clinical trial findings. Other topics pertaining to predictive biomarkers, staging, risk assessment, toxicity management, and survivorship were also addressed and are summarized in this internet-based newsletter.
. Target Audience
Medical, surgical, and radiation oncologists, and other health care professionals interested in the treatment of breast cancer.
Upon completion of this educational activity, the participant should be able to:
Describe molecular assays and biomarkers that can assess recurrence risk and predict benefit from adjuvant chemotherapy, endocrine therapy, and HER2-targeted therapy for individual patients.
Evaluate data from recent adjuvant and neoadjuvant clinical trials in order to optimize and individualize treatment with cytotoxic, endocrine, or targeted agents for patients with early-stage breast cancer.
Describe current expert guideline recommendations for the treatment of early-stage breast cancer.
Discuss the impact of breast cancer subtype on the efficacy of adjuvant chemotherapy, endocrine therapy, or targeted therapy.
Describe recent data on surgical and radiation therapy in defined patient subgroups in order to select the appropriate local control strategy for individual patients.
In compliance with ACCME guidelines, Physicians’ Education Resource, LLC (PER) is providing a list of the individuals in a position to control/influence the content of this CME activity and their relevant financial relationships with commercial interests (or absence thereof). PER has used a multi-step process to resolve all COI.
Relevant Financial Relationships With Commercial Interests
Kathy S. Albain, MD – Advisory Board Member: Genomic Health
Frankie Ann Holmes, MD – Advisory Board Member: Eisai Inc.; Speaker’s Bureau: Genentech
Stephen Jones, MD – Consultant: Genentech and Pfizer Inc; Speaker’s Bureau: Eisai Inc., Genentech, and Amgen
Joyce O’Shaughnessy, MD – Consultant: Boehringer Ingelheim International GmbH, Bristol-Myers Squibb, Caris Diagnostics, Inc., Eisai Inc., GlaxoSmithKline, Johnson and Johnson, and Roche. Speaker’s Bureau: Bristol-Myers Squibb, Celgene Corporation, Eisai Inc., and Genentech
Mark Robson, MD – Grant/Research Support: Abbott Pharmaceuticals; Consultant: Tesaro Pharmaceuticals and Bayer Pharmaceuticals
Debu Tripathy, MD – Consultant: Genentech
Andrew D. Seidman. MD – Consultant: Millenium, Genomic Health, Roche/Genentech; Speaker’s Bureau: Eisai Inc., Celgene Corporation, Genomic Health, and Roche/Genentech
No Relevant Financial Relationships With Commercial Interests
David M. Euhus, MD; Silvia C. Formenti, MD; Suzanne Fuqua, MD; Minetta Liu, MD; Eleftherios Mamounas, MD; Beth Overmoyer, MD; Andrea Richardson, MD; Ian Smith, MD; and Frank Vicini, MD, FACR.
The Staff of Physicians’ Education Resource, LLC – Susan Peck, PhD and Gregory Pynes.
The Staff of MCM Education – Joseph Kim, MD, and David Willard.
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Physicians’ Education Resource and MCM Education. Physicians’ Education Resource is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation Statement
Physicians' Education Resource designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Commercial Support Statements
This activity is supported by educational grants from Genentech, Genomic Health, and Eisai Inc.
Minimum System Requirements:
• Pentium III, 600 MHz or Equivalent Processor
• 512 MB of RAM
• Windows XP, Vista, or 7
• Mac OS X
• 800x600 Monitor Resolution
• 16-bit Color
• 16 bit Sound Card with Speakers
The next screen will permit you to check for or download the Flash player required to run this program and to begin the program presentation. The activity will take approximately 30 minutes to complete.
After the activity has finished, click on the "Post-test" button.
Instructions for completing and submitting the post-test and evaluation are provided on the post-test screen. In order to receive a CME certificate, participants must read the newsletter, complete and successfully pass the post-test with a score of 80% or higher, and complete the evaluation and request for credit. Participants may immediately download a CME certificate upon completion of these steps.
Please turn off all pop-up blockers to assure access to the educational activity.
Click on the "Start program" icon at the bottom of this page. If you are not already registered as a user of this website, this will bring you to the login/registration page where you will be able to register as a new CMEcorner.com member or check existing registration information. When ready, click on the "Continue to Program" icon at the bottom of the screen.
This CME activity will discuss the investigational, unapproved, or off-label use of drugs, including but not limited to multiple assays for prediction of benefit node-positive breast cancer, lapatinib and pertuzumab inneoadjuvant and adjuvant settings, PARP inhibitors (veliparib, olaparib, rucaparib, and iniparib). Participants are advised to consult prescribing information for all products discussed. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options for a specific patient’s medical condition.
The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of Physicians’ Education Resource, LLC, MCM Education, or any of the companies that provided commercial support for this CME activity.